GlucoTrack, Inc. Overview
Pro stress-test →GlucoTrack is a medical device company focused on developing an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company's CBGM is a long-term, implantable system that continually measures blood glucose levels with sensor longevity of 2+ years, no on-body wearable component and minimal calibration.
Strategic Profile
Pro stress-test →GlucoTrack has no meaningful revenue yet and negative earnings, but possesses peer-reviewed data in serious journals backing its main technology. Recent publications in IEEE Sensors Journal confirm year-long sensor stability in-vitro, while Journal of Diabetes Research shows 240-day accuracy in a live ovine model. As of January 2026, the USPTO issued three patents for the company's glucose monitoring technology.
Competitive Landscape
Pro stress-test →GlucoTrack competes in the continuous glucose monitoring space with differentiation through its fully implantable, long-term sensor design versus conventional wearable systems. Key established competitors include Dexcom (wearable CGM leader), Medtronic (integrated diabetes management), and Abbott FreeStyle Libre (wearable flash glucose monitoring), all of which offer wearable or minimally invasive solutions. GlucoTrack's implantable approach targets the underserved segment seeking reduced user burden.
Industry Context
GlucoTrack, Inc. operates in Continuous glucose monitoring devices.
Key facts
Headquarters: Rutherford, US · Revenue: Pre-revenue · Market cap: $2.1M